EMILY GLASS: Open Payments
NPI 1750799870 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,199 in 67 payments from 17 companies in 2025. Trend: 2023 $1,979 · 2024 $1,830 · 2025 $1,199
Food & beverage: $1,199
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $218 |
| Novo Nordisk Inc | 11 | $195 |
| Lilly USA, LLC | 10 | $174 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $96 |
| Astellas Pharma US Inc | 5 | $88 |
| GlaxoSmithKline, LLC. | 3 | $76 |
| PFIZER INC. | 4 | $62 |
| Collegium Pharmaceutical, Inc. | 3 | $53 |
| Exact Sciences Corporation | 3 | $53 |
| Abbott Laboratories | 2 | $38 |
Products named: MOUNJARO, VRAYLAR, Kerendia, Wegovy, Veozah, TRELEGY ELLIPTA, Ozempic, QULIPTA.
Industry payments across IN — which companies pay providers there.
